ABUS
Price
$4.21
Change
+$0.03 (+0.72%)
Updated
Oct 22 closing price
Capitalization
834.03M
21 days until earnings call
Intraday BUY SELL Signals
CVKD
Price
$0.97
Change
-$0.05 (-4.90%)
Updated
Oct 22 closing price
Capitalization
3.46M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABUS vs CVKD

ABUS vs CVKD Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABUS vs. CVKD commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and CVKD is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABUS with price predictions
Oct 22, 2026

ABUS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 07, 2026

ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 34 cases where ABUS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABUS's RSI Indicator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 61 cases where ABUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ABUS as a result. In 60 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for ABUS just turned positive on October 22, 2026. Looking at past instances where ABUS's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.

Following a +2.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in 183 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

ABUS moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ABUS crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 68%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

The Aroon Indicator for ABUS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.223) is normal, around the industry mean (2.973). P/E Ratio (5.329) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for CVKD with price predictions
Oct 22, 2026

CVKD's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CVKD turned positive on September 17, 2026. Looking at past instances where CVKD's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVKD's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on CVKD as a result. In 46 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

Following a +16.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in 144 of 178 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 40 cases where CVKD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

CVKD broke above its upper Bollinger Band on September 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CVKD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.846) is normal, around the industry mean (2.973). P/E Ratio (-0.199) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CVKD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABUS: Fundamental Ratings
ABUS
OUTLOOK RATING
1..100
62
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
15
PRICE GROWTH RATING
1..100
71
P/E GROWTH RATING
1..100
36
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABUSCVKD
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
72%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
76%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ABUS: $4.21 vs. CVKD: $1.02)
Brand notoriety: ABUS and CVKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 43% vs. CVKD: 5%
Market capitalization -- ABUS: $834.03M vs. CVKD: $3.46M
ABUS [@Biotechnology] is valued at $834.03M. CVKD’s [@Biotechnology] market capitalization is $3.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 1 FA rating(s) are green while CVKD’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 1 green, 4 red.
  • CVKD’s FA Score: 1 green, 4 red.
According to our system of comparison, ABUS is a better buy in the long-term than CVKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while CVKD’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 4 bearish.
  • CVKD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ABUS and CVKD are a good buy in the short-term.

Price Growth

ABUS (@Biotechnology) experienced а -1.86% price change this week, while CVKD (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 12, 2026.

CVKD is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABUS
Daily Signal:
Gain/Loss:
CVKD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with RCKT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+0.72%
RCKT - ABUS
45%
Loosely correlated
+5.00%
BCYC - ABUS
44%
Loosely correlated
+1.96%
PCVX - ABUS
43%
Loosely correlated
-0.60%
ARRY - ABUS
43%
Loosely correlated
-3.23%
AXON - ABUS
42%
Loosely correlated
+2.98%
More

CVKD and

Correlation & Price change

A.I.dvisor tells us that CVKD and RADX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVKD and RADX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVKD
1D Price
Change %
CVKD100%
-4.90%
RADX - CVKD
31%
Poorly correlated
-6.11%
GDTC - CVKD
29%
Poorly correlated
+1.72%
ABUS - CVKD
26%
Poorly correlated
+0.72%
ARTL - CVKD
26%
Poorly correlated
-0.39%
OKUR - CVKD
26%
Poorly correlated
+12.17%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HAYW12.710.65
+5.39%
Hayward Holdings
TCMD23.540.26
+1.12%
Tactile Systems Technology
GBR0.67N/A
-0.44%
New Concept Energy
AGI30.30-1.42
-4.48%
Alamos Gold
BMHL3.21-0.16
-4.75%
Bluemount Holdings Ltd